Today: 21 January 2026
Subscribe
Browse Category

NASDAQ:IBRX News 20 January 2026 - 21 January 2026

ImmunityBio (IBRX) stock slips premarket after FDA maps fresh ANKTIVA resubmission route in bladder cancer

ImmunityBio (IBRX) stock slips premarket after FDA maps fresh ANKTIVA resubmission route in bladder cancer

New York, January 21, 2026, 08:47 EST — Premarket ImmunityBio’s stock dropped 5.9% to $6.10 in premarket trading Wednesday. The move followed the company’s announcement of a meeting with the U.S. Food and Drug Administration to discuss a possible resubmission of its bladder-cancer treatment, ANKTIVA. (MarketScreener) This move is significant because the FDA rejected ImmunityBio’s application last year to expand…
21 January 2026
·····
ImmunityBio (IBRX) stock jumps on FDA’s 30-day ANKTIVA resubmission path — what’s next

ImmunityBio (IBRX) stock jumps on FDA’s 30-day ANKTIVA resubmission path — what’s next

New York, January 20, 2026, 20:22 ET — The market has closed. Shares of ImmunityBio, listed on Nasdaq, surged Tuesday following news that U.S. regulators outlined a potential path for the company to pursue an expanded bladder cancer indication for its drug ANKTIVA. The stock closed up 17.7% at $6.48, after trading between $4.94 and $7.97 on heavy volume. (Business…
21 January 2026
·····
ImmunityBio (IBRX) stock jumps after FDA signals ANKTIVA resubmission path in bladder cancer

ImmunityBio (IBRX) stock jumps after FDA signals ANKTIVA resubmission path in bladder cancer

New York, January 20, 2026, 12:42 ET — Regular session ImmunityBio, Inc. shares climbed roughly 24% to $6.82 by midday Tuesday after the company revealed the U.S. Food and Drug Administration provided guidance that could pave the way for a resubmission of its bladder cancer drug ANKTIVA. Earlier, the stock hit $7.97, fluctuating between $4.94 and $7.97 on about 159…
20 January 2026
····

Stock Market Today

  • Will the Stock Market Crash in 2026? Investors Urged to Prioritize Strong Companies
    January 21, 2026, 1:18 PM EST. Investors are increasingly anxious as the Buffett indicator, measuring U.S. stock market value against GDP, hits a record 223%, signaling possible overvaluation. Historically, bubbles like the 2000 dot-com crash wiped out weak firms, while strong companies such as Amazon eventually recovered and soared. Experts advise focusing on robust businesses with solid fundamentals-like manageable debt levels and reasonable price-to-earnings ratios-and reliable leadership. These firms typically endure downturns better. With 80% of Americans worried about recession risks, preparing portfolios by emphasizing quality stocks is a prudent move amid 2026 market uncertainties.
Go toTop